Pharma BD Deal Intelligence
A $589M stock deal that built Barr's women's health franchise, which anchored Barr's own $7.46B sale to Teva in 2008 and still operates today as Teva Women's Health.
Full analysis, sources & comparables →The merger will create a leading developer, manufacturer and marketer of proprietary and generic female healthcare products... Barr expects the transaction to…
Barr Laboratories has signed a definitive agreement to acquire Duramed Pharmaceuticals in a transaction that is being valued by observers at around…
C&EN noted that in 1999 the FDA had approved Cenestin (Duramed) as the second conjugated estrogen product after Wyeth's long-dominant Premarin, in a market…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
$589M stock swap (some sources $571M). Strategic move from pure-play generics into branded women's health (Cenestin).
A $589M stock deal that built Barr's women's health franchise, which anchored Barr's own $7.46B sale to Teva in 2008 and still operates today as Teva Women's Health.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. (this deal) | 2001 | $589M | 82 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
| Abbott Laboratories / Vysis Inc. | 2001 | $355M | 79 |
← Browse all deals · How we score deals
More: 2001 deals